MDR1 (C3435T) polymorphism: Relation to the risk of breast cancer and therapeutic outcome

Pharmacogenomics Journal

Volumn 10, Issue 1, 2010, Pages 62-69

  Cizmarikova, M ^a   Wagnerova, M ^b   Schonova, L ^a   Habalova, V ^a   Kohut, A ^a   Linkova, A ^a   Sarissky, M ^a   Mojzis, J ^a   Mirossay, L ^a   Mirossay, A ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b Vychodoslovensky Onkologicky Ustav Kosice   (Slovakia)

Author keywords

Anthracycline; Breast cancer; MDR1 polymorphism; P glycoprotein; Therapeutic outcome; Toxicity

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYTOSINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 1; THYMINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE FREQUENCY; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 75549088665     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.41     Document Type: Article

References (31)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592. (Pubitemid 46359643)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
3. Lester J. Breast cancer in 2007: incidence, risk assessment, and risk reduction strategies. Clin J Oncol Nurs 2007; 11: 619-622.
4. Fossland VS, Stroop JB, Schwartz RC, Kurtzman SH. Genetic issues in patients with breast cancer. Surg Oncol Clin N Am 2009; 18: 53-71.
5. Stearns V, Davidson NE, Flockhart DA. Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 2004; 4: 143-153.
6. Robert J, Le Morvan V, Smith D, Pourquier P, Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005; 54: 171-196.
7. Zhou SF. Structure, function and regulation of p-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008; 38: 802-832.
8. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204: 216-237.
9. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006; 234: 4-33.
10. Fromm MF. The influence of MDR1 polymorphisms on p-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54: 1295-1310.
11. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003; 10: 43-73.
12. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
13. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525-528.
14. C3435T polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847-1854.
15. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007; 7: 154-179.
16. Ferguson LR, De Flora S. Multiple drug resistance, antimutagenesis and anticarcinogenesis. Mutat Res 2005; 591: 24-33.
17. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008; 38: 802-832.
18. Kurzawski M, DroŸdzik M, Suchy J, Kurzawski G, Bia"ecka M, Górnik W. Polymorphism in the p-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 2005; 61: 389-394.
19. Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004; 72: 314-321.
20. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62: 4955-4962.
21. DeBruin LS, Josephy PD. Perspectives on the chemical etiology of breast cancer. Environ Health Perspect 2002; 110: 119-128.
22. Turgut S, Yaren A, Kursunluoglu R, Turgut G. MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res 2007; 38: 539-544.
23. Tatari F, Salek R, Mosaffa F, Khedri A, Behravan J. Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population. DNA Cell Biol 2009; 28: 259-263.
24. Gervasini G, Carrillo JA, Garcia M, San JC, Cabanillas A, Benitez J. Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T A gene polymorphism is associated with high risk of lung cancer. Cancer 2006; 107: 2850-2857.
25. Stanulla M, Schäffeler E, Arens S, Rathmann A, Scharauder A, Welte K et al. GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hemato 2005; 81: 39-44.
26. Miller KL, Kelsey KT, Wiencke JK, Moghadassi M, Miike R, Liu M et al. The C3435T polymorphism of MDR1 and susceptibility to adult glioma. Neuroepidemiology 2005; 25: 85-90.
27. Gerlach JH, Kartner N, Bell DR, Ling V. Multidrug resistance. Cancer Surv 1986; 5: 25-46.
28. Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003; 22: 1117-1121.
29. Rodrigues FFO, Santos RE, Melo MB, Silva MALG, Oliveira AL, Rozenowicz RL et al. Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet Mol Res 2008; 7: 177-183.
30. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451-2458.
31. Oselin K, Nowakowski-Gashaw I, Mrozikiewicz PM, Wolbergs D, Pahkla R, Roots I. Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. Eur J Clin Invest 2003; 33: 261-267.